EyePoint, Inc.
Moat Score — EyePoint, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | EyePoint's patented Durasert bioerodible sustained-release implant platform, built on years of proprietary formulation and manufacturing know-how, is a genuine and hard-to-replicate technology moat underlying its entire pipeline and licensing strategy. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | EyePoint is not competing on manufacturing or operating cost; it is a smaller, capital-constrained biopharma competing against much larger incumbents like Regeneron and Roche on clinical and commercial execution, not cost. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Pricing power for any future approved EyePoint product will be constrained by payer negotiations and comparison to entrenched, already-reimbursed anti-VEGF therapies, limiting EyePoint's ability to command premium pricing without clearly superior outcomes data. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in ophthalmic drug delivery -- one patient's treatment does not make the therapy more valuable or effective for the next patient. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | If EYP-1901 or similar candidates reach approval and reduce injection frequency, retina specialists and patients who adopt the therapy and see reduced treatment burden would have real reason to stay, though this advantage is not yet proven commercially. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The wet AMD and broader retinal disease treatment market is large and already supports multiple well-funded incumbents and emerging gene-therapy and sustained-release competitors, so the market is not naturally limited to just EyePoint's approach. |